The Blood Xenotropic Murine Leukemia Virus–Related Virus Scientific Research Working Group: mission, progress, and plans

Authors

  • Graham Simmons,

    1. From the Blood Systems Research Institute and University of California, San Francisco, California; the Transfusion Medicine and Cellular Therapeutics Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland; the Department of Health and Human Services, Washington, DC; National Cancer Institute, Bethesda, Maryland; Tufts University School of Medicine, Boston, Massachusetts; Office of Blood Research and Review and the Division of Cellular and Gene Therapies Review, Food and Drug Administration, Silver Spring, Maryland; the Whittemore Peterson Institute and University of Nevada, Reno, Nevada; the Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; and Gen-Probe, Inc., San Diego, California.
    Search for more papers by this author
  • Simone A. Glynn,

    1. From the Blood Systems Research Institute and University of California, San Francisco, California; the Transfusion Medicine and Cellular Therapeutics Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland; the Department of Health and Human Services, Washington, DC; National Cancer Institute, Bethesda, Maryland; Tufts University School of Medicine, Boston, Massachusetts; Office of Blood Research and Review and the Division of Cellular and Gene Therapies Review, Food and Drug Administration, Silver Spring, Maryland; the Whittemore Peterson Institute and University of Nevada, Reno, Nevada; the Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; and Gen-Probe, Inc., San Diego, California.
    Search for more papers by this author
  • Jerry A. Holmberg,

    1. From the Blood Systems Research Institute and University of California, San Francisco, California; the Transfusion Medicine and Cellular Therapeutics Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland; the Department of Health and Human Services, Washington, DC; National Cancer Institute, Bethesda, Maryland; Tufts University School of Medicine, Boston, Massachusetts; Office of Blood Research and Review and the Division of Cellular and Gene Therapies Review, Food and Drug Administration, Silver Spring, Maryland; the Whittemore Peterson Institute and University of Nevada, Reno, Nevada; the Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; and Gen-Probe, Inc., San Diego, California.
    Search for more papers by this author
  • John M. Coffin,

    1. From the Blood Systems Research Institute and University of California, San Francisco, California; the Transfusion Medicine and Cellular Therapeutics Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland; the Department of Health and Human Services, Washington, DC; National Cancer Institute, Bethesda, Maryland; Tufts University School of Medicine, Boston, Massachusetts; Office of Blood Research and Review and the Division of Cellular and Gene Therapies Review, Food and Drug Administration, Silver Spring, Maryland; the Whittemore Peterson Institute and University of Nevada, Reno, Nevada; the Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; and Gen-Probe, Inc., San Diego, California.
    Search for more papers by this author
  • Indira K. Hewlett,

    1. From the Blood Systems Research Institute and University of California, San Francisco, California; the Transfusion Medicine and Cellular Therapeutics Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland; the Department of Health and Human Services, Washington, DC; National Cancer Institute, Bethesda, Maryland; Tufts University School of Medicine, Boston, Massachusetts; Office of Blood Research and Review and the Division of Cellular and Gene Therapies Review, Food and Drug Administration, Silver Spring, Maryland; the Whittemore Peterson Institute and University of Nevada, Reno, Nevada; the Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; and Gen-Probe, Inc., San Diego, California.
    Search for more papers by this author
  • Shyh-Ching Lo,

    1. From the Blood Systems Research Institute and University of California, San Francisco, California; the Transfusion Medicine and Cellular Therapeutics Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland; the Department of Health and Human Services, Washington, DC; National Cancer Institute, Bethesda, Maryland; Tufts University School of Medicine, Boston, Massachusetts; Office of Blood Research and Review and the Division of Cellular and Gene Therapies Review, Food and Drug Administration, Silver Spring, Maryland; the Whittemore Peterson Institute and University of Nevada, Reno, Nevada; the Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; and Gen-Probe, Inc., San Diego, California.
    Search for more papers by this author
  • Judy A. Mikovits,

    1. From the Blood Systems Research Institute and University of California, San Francisco, California; the Transfusion Medicine and Cellular Therapeutics Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland; the Department of Health and Human Services, Washington, DC; National Cancer Institute, Bethesda, Maryland; Tufts University School of Medicine, Boston, Massachusetts; Office of Blood Research and Review and the Division of Cellular and Gene Therapies Review, Food and Drug Administration, Silver Spring, Maryland; the Whittemore Peterson Institute and University of Nevada, Reno, Nevada; the Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; and Gen-Probe, Inc., San Diego, California.
    Search for more papers by this author
  • William M. Switzer,

    1. From the Blood Systems Research Institute and University of California, San Francisco, California; the Transfusion Medicine and Cellular Therapeutics Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland; the Department of Health and Human Services, Washington, DC; National Cancer Institute, Bethesda, Maryland; Tufts University School of Medicine, Boston, Massachusetts; Office of Blood Research and Review and the Division of Cellular and Gene Therapies Review, Food and Drug Administration, Silver Spring, Maryland; the Whittemore Peterson Institute and University of Nevada, Reno, Nevada; the Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; and Gen-Probe, Inc., San Diego, California.
    Search for more papers by this author
  • Jeffrey M. Linnen,

    1. From the Blood Systems Research Institute and University of California, San Francisco, California; the Transfusion Medicine and Cellular Therapeutics Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland; the Department of Health and Human Services, Washington, DC; National Cancer Institute, Bethesda, Maryland; Tufts University School of Medicine, Boston, Massachusetts; Office of Blood Research and Review and the Division of Cellular and Gene Therapies Review, Food and Drug Administration, Silver Spring, Maryland; the Whittemore Peterson Institute and University of Nevada, Reno, Nevada; the Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; and Gen-Probe, Inc., San Diego, California.
    Search for more papers by this author
  • Michael P. Busch,

    1. From the Blood Systems Research Institute and University of California, San Francisco, California; the Transfusion Medicine and Cellular Therapeutics Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland; the Department of Health and Human Services, Washington, DC; National Cancer Institute, Bethesda, Maryland; Tufts University School of Medicine, Boston, Massachusetts; Office of Blood Research and Review and the Division of Cellular and Gene Therapies Review, Food and Drug Administration, Silver Spring, Maryland; the Whittemore Peterson Institute and University of Nevada, Reno, Nevada; the Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; and Gen-Probe, Inc., San Diego, California.
    Search for more papers by this author
  • for the Blood XMRV Scientific Research Working Group


  • The views expressed do not necessarily represent the view of the Department of Health and Human Services or the US Federal Government.

Graham Simmons, Blood Systems Research Institute and University of California, San Francisco, 270 Masonic Ave, San Francisco, CA 94118; e-mail: gsimmons@bloodsystems.org; Simone A. Glynn, Transfusion Medicine and Cellular Therapeutics Branch, National Heart, Lung, and Blood Institute, Division of Blood Diseases and Resources, Rockledge Two, 6701 Rockledge Drive, Room 9142, NIH, Bethesda, MD 20892-7950; e-mail: glynnsa@nhlbi.nih.gov.

Ancillary